Days after an 8% selloff, Novo pays a microcap up to $1.3B to make its shots monthly
Novo Nordisk licensed Nanexa's PharmaShell coating for up to €1.165 billion, three days after its Capital Markets Day cost shareholders 8%. The bet: monthly and quarterly needles are the moat against Eli Lilly and semaglutide's 2032 patent cliff.
Vincent Jiang · 3 min read
On Friday morning in Stockholm, shares in Nanexa, a drug-delivery company that booked $3.89 million of revenue in 2025, opened up more than 150%, touched 15.50 kronor against Thursday's 5.93 close, their highest in more than five years, and held a gain near 114% into late morning 123. The trigger was one signature: after Thursday's close, Novo Nordisk licensed Nanexa's PharmaShell technology for up to €1.165 billion 24.
Novo bought the weeks between needles
PharmaShell wraps each drug particle in an ultra-thin inorganic coating, applied atom by atom, so it releases over weeks instead of hours 4. Novo gets exclusive global rights for up to five cardiometabolic programs, with monthly and quarterly injections as target profiles against the weekly standard 24. Nanexa is eligible for €615 million in upfront payment plus development and regulatory milestones, the remainder in sales milestones, and low single-digit royalties on global net sales; Novo leads development and commercialization 4. The split inside the €615 million is undisclosed. Novo did not buy a molecule; it bought the weeks between needles.
Monday's promise, marked down 8%
The deal landed three days after Novo's Capital Markets Day, where management promised 2026-2030 revenue growth in line with industry peers, more than five multi-blockbuster launches by 2030, and over DKK 150 billion of risk-adjusted pipeline sales in 2035 56. Investors took roughly 8% off both listings 6, and BMO read the growth promise as a 3.53% CAGR against 3.65% for peers 6. The same launch calendar quietly slots a monthly-dose GLP-1 for 2030, while CEO Mike Doustdar calls semaglutide's 2032 US loss of exclusivity "the elephant in the room" 6. His verdict on the selloff: "we still need to do more work on building trust" 7.
Lilly owns the tape, Novo owns the calendar
The gap being hedged is blunt. Lilly's Mounjaro and Zepbound sold a combined $27.6 billion in the first half against $15.7 billion for Novo's whole GLP-1 shelf, and Lilly's pill Foundayo added $98 million in its first quarter 6. Ozempic revenue fell 8% year over year 6, and Novo's reported growth has swung from 26.3% in the September 2024 quarter to minus 0.8% in the June quarter 8. Novo hedged both formats inside one week: up to $1.4 billion to Orbis Medicines for oral macrocycles in the run-up to the event, PharmaShell for injection duration three days after it 6.
Novo's growth has swung from 26% to minus 0.8% in seven quarters
Data
| Revenue growth (YoY) | |
|---|---|
| Q1 '24 | 21% |
| Q2 '24 | 23.4% |
| Q3 '24 | 26.3% |
| Q4 '24 | 22.5% |
| Q1 '25 | 19.8% |
| Q2 '25 | 23.6% |
| Q3 '25 | 12.1% |
| Q4 '25 | 4.1% |
| Q1 '26 | 31% |
| Q2 '26 | -0.8% |
Lilly's two injectables outsold Novo's whole GLP-1 shelf in H1 2026
Data
| Value | |
|---|---|
| Mounjaro (Lilly) | $18.61B |
| Zepbound (Lilly) | $9.09B |
| Ozempic (Novo) | $9.09B |
| Wegovy jab (Novo) | $5.79B |
| Wegovy pill (Novo) | $0.84B |
The milestones protect the cash, not the wait
The other side is real. Most of the €1.165 billion pays out only if programs succeed and sell, so Thursday's cash cost is modest 4. Convenience moves share, not just sentiment: more than 80% of US patients starting Novo's Wegovy pill had never taken a GLP-1 7. Nanexa is a proven counterparty, having licensed PharmaShell to Moderna in 2025 4. None of it shortens the timeline: five unnamed programs, monthly dosing dated 2030 26.
What to watch next
Three markers: the upfront figure when Nanexa discloses it, the first named PharmaShell program, and whether the monthly GLP-1 keeps its 2030 slot 46. Novo has already cut 13,000 jobs to redirect DKK 10 billion toward the pipeline 6. Nanexa's shareholders were paid on Friday; Novo's are being asked to wait.
How this brief was made
01Gathered & sourced356 channels · 1,994 articles▾
Agents swept 356 channels and ingested 1,994 articles, then de-duplicated and ranked them for signal.
02Verified & cross-validated8 claims · 10 data feeds▾
Every one of 8 load-bearing claims was checked against primary sources, with 10 live data feeds reconciling the figures and charts.
- 1CNBC, Pharma stock soars 150% on injectables deal with Wegovy maker Novo, 25 September 2026
- 2IJR, Novo Nordisk Signs Nanexa Deal Up to $1.3B, 25 September 2026
- 3Reuters (via MSN), Nanexa shares soar on €1.17 billion Novo Nordisk deal for injection technology, 25 September 2026
- 4Nanexa AB, Nanexa and Novo enter into EUR 1.165 billion global license and collaboration agreement for long-acting injectables, 24 September 2026
- 5Novo Nordisk via GlobeNewswire/StreetInsider, Highlights to be presented at Novo's Capital Markets Day 2026, 21 September 2026
- 6GEN News, StockWatch: Novo's 2030 Strategy Underwhelms Investors at Capital Markets Day, 21 September 2026
- 7CNBC, Novo's new strategy hinges on something it can't manufacture: investor trust, 24 September 2026
- 8Sharadar quarterly fundamentals, from Novo Nordisk's SEC filings, retrieved 26 September 2026
03Reviewed & edited1 human editor▾
One editor read the draft against the evidence, tuned the framing, and signed off before it shipped.
Become a contributor
Reporting on the business of AI and want it read? We take pitches from outside contributors who bring primary sources and a number worth arguing about.
Deepdive
AI-generated from this story and its cited sources. Not investment advice.
